Trial Watch

References

• Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9:269 - 77; http://dx.doi.org/10.1038/nm0303-269; PMID: 12612576
   PubMed Web of Science ®Google Scholar
• Finn OJ. Tumor immunology at the service of cancer immunotherapy. Curr Opin Immunol 2004; 16:127 - 9; http://dx.doi.org/10.1016/j.coi.2004.02.006; PMID: 15023402
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991 - 1045; http://dx.doi.org/10.1146/annurev.iy.12.040194.005015; PMID: 8011301
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643 - 7; http://dx.doi.org/10.1126/science.1840703; PMID: 1840703
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; http://dx.doi.org/10.4161/onci.25771; PMID: 24286020
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111 - 34; http://dx.doi.org/10.4161/onci.21494; PMID: 23170259
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265 - 77; http://dx.doi.org/10.1038/nrc3258; PMID: 22437871
   PubMed Web of Science ®Google Scholar
• Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8:351 - 60; http://dx.doi.org/10.1038/nrc2373; PMID: 18418403
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; http://dx.doi.org/10.4161/onci.26621; PMID: 24498550
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557 - 76; http://dx.doi.org/10.4161/onci.22428; PMID: 23264902
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108 - 20; http://dx.doi.org/10.1038/nrc2326; PMID: 18219306
   PubMed Web of Science ®Google Scholar
• Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010; 2010:174378; http://dx.doi.org/10.1155/2010/174378; PMID: 20368780
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239:62 - 84; http://dx.doi.org/10.1111/j.1600-065X.2010.00980.x; PMID: 21198665
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol 2010; 22:264 - 70; http://dx.doi.org/10.1016/j.coi.2010.01.019; PMID: 20172703
   PubMed Web of Science ®Google Scholar
• Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2:985 - 91; http://dx.doi.org/10.1038/nm0996-985; PMID: 8782455
   PubMed Web of Science ®Google Scholar
• Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22:181 - 5; http://dx.doi.org/10.1016/j.ceb.2009.12.001; PMID: 20044243
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Morselli E, Kepp O, Tajeddine N, Kroemer G. Targeting p53 to mitochondria for cancer therapy. Cell Cycle 2008; 7:1949 - 55; http://dx.doi.org/10.4161/cc.7.13.6222; PMID: 18642442
   PubMed Web of Science ®Google Scholar
• INGN. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D 2007; 8:176 - 87; http://dx.doi.org/10.2165/00126839-200708030-00005; PMID: 17472413
   PubMedGoogle Scholar
• Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. Mol Ther 2009; 17:1651 - 7; http://dx.doi.org/10.1038/mt.2009.126; PMID: 19532136
   PubMed Web of Science ®Google Scholar
• Madhusudan S, Tamir A, Bates N, Flanagan E, Gore ME, Barton DP, Harper P, Seckl M, Thomas H, Lemoine NR, et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004; 10:2986 - 96; http://dx.doi.org/10.1158/1078-0432.CCR-03-0291; PMID: 15131034
   PubMed Web of Science ®Google Scholar
• Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001; 7:1237 - 45; PMID: 11350889
   PubMed Web of Science ®Google Scholar
• Xing X, Liu V, Xia W, Stephens LC, Huang L, Lopez-Berestein G, Hung MC. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice. Gene Ther 1997; 4:238 - 43; http://dx.doi.org/10.1038/sj.gt.3300376; PMID: 9135737
   PubMed Web of Science ®Google Scholar
• Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, Hung MC. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther 1998; 5:1538 - 44; http://dx.doi.org/10.1038/sj.gt.3300771; PMID: 9930307
   PubMed Web of Science ®Google Scholar
• Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther 2010; 12:607 - 16; PMID: 20886393
   PubMed Web of Science ®Google Scholar
• Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, Appelbaum L, Kopelman Y, Czerniak A, Hochberg A. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther 2012; 19:374 - 81; http://dx.doi.org/10.1038/cgt.2012.10; PMID: 22498722
   PubMed Web of Science ®Google Scholar
• Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 1:195 - 203; http://dx.doi.org/10.1006/mthe.2000.0030; PMID: 10933931
   PubMed Web of Science ®Google Scholar
• Singh S, Cunningham C, Buchanan A, Jolly DJ, Nemunaitis J. Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer. Mol Ther 2001; 4:157 - 60; http://dx.doi.org/10.1006/mthe.2001.0430; PMID: 11482988
   PubMed Web of Science ®Google Scholar
• Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003; 65:279 - 89; http://dx.doi.org/10.1023/B:NEON.0000003657.95085.56; PMID: 14682378
   PubMed Web of Science ®Google Scholar
• Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, Kracht L, Coenen HH, Sturm V, Wienhard K, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003; 54:479 - 87; http://dx.doi.org/10.1002/ana.10688; PMID: 14520660
   PubMed Web of Science ®Google Scholar
• Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, Kao C, Lim SD, Amin MB, Yang H, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14:227 - 41; http://dx.doi.org/10.1089/10430340360535788; PMID: 12639303
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill A, Clairmont C, Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003; 10:737 - 44; http://dx.doi.org/10.1038/sj.cgt.7700634; PMID: 14502226
   PubMed Web of Science ®Google Scholar
• Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y, et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 2003; 10:755 - 63; http://dx.doi.org/10.1038/sj.cgt.7700626; PMID: 14502228
   PubMed Web of Science ®Google Scholar
• Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999; 17:3313 - 23; PMID: 10506635
   PubMed Web of Science ®Google Scholar
• Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, Hinkel A, deKernion J, Figlin R. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12:883 - 92; http://dx.doi.org/10.1089/104303401750195854; PMID: 11387054
   PubMed Web of Science ®Google Scholar
• Horton HM, Lalor PA, Rolland AP. IL-2 plasmid electroporation: from preclinical studies to phase I clinical trial. Methods Mol Biol 2008; 423:361 - 72; http://dx.doi.org/10.1007/978-1-59745-194-9_28; PMID: 18370214
   PubMedGoogle Scholar
• Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, Elzaouk L, Pavlovic J, Moelling K. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005; 16:35 - 48; http://dx.doi.org/10.1089/hum.2005.16.35; PMID: 15703487
   PubMed Web of Science ®Google Scholar
• Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P. Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial. Cancer Gene Ther 2007; 14:717 - 23; http://dx.doi.org/10.1038/sj.cgt.7701064; PMID: 17557109
   PubMed Web of Science ®Google Scholar
• Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26:5896 - 903; PMID: 19029422
   PubMed Web of Science ®Google Scholar
• Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 2010; 17:360 - 9; http://dx.doi.org/10.1038/gt.2009.159; PMID: 20033066
   PubMed Web of Science ®Google Scholar
• Hernandez-Alcoceba R, Berraondo P. Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin. Oncoimmunology 2012; 1:97 - 9; http://dx.doi.org/10.4161/onci.1.1.17930; PMID: 22720223
   PubMed Web of Science ®Google Scholar
• Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, Rosell K, Whiteside T, Phillippe S, Acres B, et al. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther 2003; 10:251 - 9; http://dx.doi.org/10.1038/sj.cgt.7700568; PMID: 12679797
   PubMed Web of Science ®Google Scholar
• Dummer R, Hassel JC, Fellenberg F, Eichmüller S, Maier T, Slos P, Acres B, Bleuzen P, Bataille V, Squiban P, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004; 104:1631 - 8; http://dx.doi.org/10.1182/blood-2004-01-0360; PMID: 15161670
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Fong T, Robbins JM, Edelman G, Edwards W, Paulson RS, Bruce J, Ognoskie N, Wynne D, Pike M, et al. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther 1999; 6:322 - 30; http://dx.doi.org/10.1038/sj.cgt.7700019; PMID: 10419050
   PubMed Web of Science ®Google Scholar
• Merrick AE, Ilett EJ, Melcher AA. JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs 2009; 10:1372 - 82; PMID: 19943208
   PubMed Web of Science ®Google Scholar
• Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gårdmark T, Tötterman TH. AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial. Clin Cancer Res 2010; 16:3279 - 87; http://dx.doi.org/10.1158/1078-0432.CCR-10-0385; PMID: 20448220
   PubMed Web of Science ®Google Scholar
• Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps TJ. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res 2012; 72:2937 - 48; http://dx.doi.org/10.1158/0008-5472.CAN-11-3368; PMID: 22505652
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 1993; 90:11307 - 11; http://dx.doi.org/10.1073/pnas.90.23.11307; PMID: 8248244
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chang AE. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996; 93:15388 - 93; http://dx.doi.org/10.1073/pnas.93.26.15388; PMID: 8986821
   PubMed Web of Science ®Google Scholar
• Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, Reading CC, Lewis BD, Stahl S, Akporiaye ET, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997; 4:419 - 25; http://dx.doi.org/10.1038/sj.gt.3300396; PMID: 9274718
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, Warneke J, Schluter SF, Stahl S. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997; 15:341 - 9; PMID: 8996161
   PubMed Web of Science ®Google Scholar
• Gleich LL, Gluckman JL, Armstrong S, Biddinger PW, Miller MA, Balakrishnan K, Wilson KM, Saavedra HI, Stambrook PJ. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg 1998; 124:1097 - 104; http://dx.doi.org/10.1001/archotol.124.10.1097; PMID: 9776187
   PubMed Web of Science ®Google Scholar
• Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999; 5:2766 - 72; PMID: 10537340
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7:2285 - 91; PMID: 11489803
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006; 16:521 - 6; http://dx.doi.org/10.1097/01.cmr.0000232299.44902.41; PMID: 17119453
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010; 20:218 - 26; PMID: 20354459
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; http://dx.doi.org/10.4161/onci.23803; PMID: 23734328
   PubMed Web of Science ®Google Scholar
• Haniffa M, Collin M, Ginhoux F. Identification of human tissue cross-presenting dendritic cells: A new target for cancer vaccines. Oncoimmunology 2013; 2:e23140; http://dx.doi.org/10.4161/onci.23140; PMID: 23802067
   PubMed Web of Science ®Google Scholar
• Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer J 2011; 17:359 - 71; http://dx.doi.org/10.1097/PPO.0b013e3182325e63; PMID: 21952287
   PubMed Web of Science ®Google Scholar
• Cawood R, Hills T, Wong SL, Alamoudi AA, Beadle S, Fisher KD, Seymour LW. Recombinant viral vaccines for cancer. Trends Mol Med 2012; 18:564 - 74; http://dx.doi.org/10.1016/j.molmed.2012.07.007; PMID: 22917663
   PubMed Web of Science ®Google Scholar
• Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, Bramson JL, Wan Y. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology 2013; 2:e26013; http://dx.doi.org/10.4161/onci.26013; PMID: 24083086
   PubMed Web of Science ®Google Scholar
• Zhou Q, Buchholz CJ. Cell type specific gene delivery by lentiviral vectors: New options in immunotherapy. Oncoimmunology 2013; 2:e22566; http://dx.doi.org/10.4161/onci.22566; PMID: 23483777
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415 - 9; http://dx.doi.org/10.1126/science.1088547; PMID: 14564000
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; http://dx.doi.org/10.4161/onci.25238; PMID: 24083080
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894 - 907; http://dx.doi.org/10.4161/onci.20931; PMID: 23162757
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699 - 716; http://dx.doi.org/10.4161/onci.20696; PMID: 22934262
   PubMed Web of Science ®Google Scholar
• Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7:175 - 91; http://dx.doi.org/10.1586/14760584.7.2.175; PMID: 18324888
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D, Romero P, Jichlinski P. What is the influence of vaccination’s routes on the regression of tumors located at mucosal sites?. Oncoimmunology 2012; 1:242 - 3; http://dx.doi.org/10.4161/onci.1.2.18204; PMID: 22720257
   PubMed Web of Science ®Google Scholar
• Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000; 165:2850 - 8; PMID: 10946318
   PubMed Web of Science ®Google Scholar
• Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009; 27:5450 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.07.005; PMID: 19622402
   PubMed Web of Science ®Google Scholar
• Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006; 40:86 - 97; http://dx.doi.org/10.1016/j.ymeth.2006.05.022; PMID: 16997717
   PubMed Web of Science ®Google Scholar
• Hallermalm K, Johansson S, Bråve A, Ek M, Engström G, Boberg A, Gudmundsdotter L, Blomberg P, Mellstedt H, Stout R, et al. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand J Immunol 2007; 66:43 - 51; http://dx.doi.org/10.1111/j.1365-3083.2007.01945.x; PMID: 17587345
   PubMed Web of Science ®Google Scholar
• Nguyen-Hoai T, Kobelt D, Hohn O, Vu MD, Schlag PM, Dörken B, Norley S, Lipp M, Walther W, Pezzutto A, et al. HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity. Oncoimmunology 2012; 1:1537 - 45; http://dx.doi.org/10.4161/onci.22563; PMID: 23264900
   PubMed Web of Science ®Google Scholar
• van den Berg JH, Nujien B, Beijnen JH, Vincent A, van Tinteren H, Kluge J, Woerdeman LA, Hennink WE, Storm G, Schumacher TN, et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009; 20:181 - 9; http://dx.doi.org/10.1089/hum.2008.073; PMID: 19301471
   PubMed Web of Science ®Google Scholar
• Fest S, Huebener N, Bleeke M, Durmus T, Stermann A, Woehler A, Baykan B, Zenclussen AC, Michalsky E, Jaeger IS, et al. Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer 2009; 125:104 - 14; http://dx.doi.org/10.1002/ijc.24291; PMID: 19291796
   PubMed Web of Science ®Google Scholar
• Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, et al. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 2012; 12:361; http://dx.doi.org/10.1186/1471-2407-12-361; PMID: 22906006
   PubMed Web of Science ®Google Scholar
• Meng JZ, Dong YJ, Huang H, Li S, Zhong Y, Liu SL, Wang YD. Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses. Clin Vaccine Immunol 2010; 17:889 - 94; http://dx.doi.org/10.1128/CVI.00044-10; PMID: 20375244
   PubMed Web of Science ®Google Scholar
• Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008; 82:5643 - 9; http://dx.doi.org/10.1128/JVI.02564-07; PMID: 18353952
   PubMed Web of Science ®Google Scholar
• Ahlén G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, Blomberg P, Fons M, Mathiesen I, Sällberg M. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007; 179:4741 - 53; PMID: 17878373
   PubMed Web of Science ®Google Scholar
• Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005; 174:6292 - 8; PMID: 15879128
   PubMed Web of Science ®Google Scholar
• Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16:867 - 70; http://dx.doi.org/10.1038/nbt0998-867; PMID: 9743122
   PubMed Web of Science ®Google Scholar
• Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6:508 - 14; http://dx.doi.org/10.1038/sj.gt.3300847; PMID: 10476210
   PubMed Web of Science ®Google Scholar
• Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci U S A 1999; 96:4262 - 7; http://dx.doi.org/10.1073/pnas.96.8.4262; PMID: 10200250
   PubMed Web of Science ®Google Scholar
• Murakami T, Sunada Y. Plasmid DNA gene therapy by electroporation: principles and recent advances. Curr Gene Ther 2011; 11:447 - 56; http://dx.doi.org/10.2174/156652311798192860; PMID: 22023474
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013; 2:e26536; http://dx.doi.org/10.4161/onci.26536; PMID: 24404424
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51 - 72; http://dx.doi.org/10.1146/annurev-immunol-032712-100008; PMID: 23157435
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780 - 8; http://dx.doi.org/10.1038/nrm3479; PMID: 23175281
   PubMed Web of Science ®Google Scholar
• Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5:615 - 25; http://dx.doi.org/10.1038/nrc1669; PMID: 16034368
   PubMed Web of Science ®Google Scholar
• Suri A, Saini S, Sinha A, Agarwal S, Verma A, Parashar D, Singh S, Gupta N, Jagadish N. Cancer testis antigens: A new paradigm for cancer therapy. Oncoimmunology 2012; 1:1194 - 6; http://dx.doi.org/10.4161/onci.20686; PMID: 23170277
   PubMed Web of Science ®Google Scholar
• Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001; 75:4040 - 7; http://dx.doi.org/10.1128/JVI.75.9.4040-4047.2001; PMID: 11287553
   PubMed Web of Science ®Google Scholar
• Anderson ED, Mourich DV, Leong JA. Gene expression in rainbow trout (Oncorhynchus mykiss) following intramuscular injection of DNA. Mol Mar Biol Biotechnol 1996; 5:105 - 13; PMID: 8680523
   PubMedGoogle Scholar
• Anderson ED, Mourich DV, Fahrenkrug SC, LaPatra S, Shepherd J, Leong JA. Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus. Mol Mar Biol Biotechnol 1996; 5:114 - 22; PMID: 8680524
   PubMedGoogle Scholar
• Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9:1284 - 90; PMID: 12684396
   PubMed Web of Science ®Google Scholar
• Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med 2013; 11:62; http://dx.doi.org/10.1186/1479-5876-11-62; PMID: 23497415
   PubMed Web of Science ®Google Scholar
• Eriksson F, Tötterman T, Maltais AK, Pisa P, Yachnin J. DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine 2013; 31:3843 - 8; http://dx.doi.org/10.1016/j.vaccine.2013.06.063; PMID: 23831327
   PubMed Web of Science ®Google Scholar
• Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE, Mohanakumar T. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells. Breast Cancer Res Treat 2013; 138:109 - 18; http://dx.doi.org/10.1007/s10549-012-2110-9; PMID: 22678162
   PubMed Web of Science ®Google Scholar
• Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 2014; 63:225 - 34; http://dx.doi.org/10.1007/s00262-013-1505-8; PMID: 24327292
   PubMed Web of Science ®Google Scholar
• Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res 2013; 73:1676 - 88; http://dx.doi.org/10.1158/0008-5472.CAN-12-2448; PMID: 23348421
   PubMed Web of Science ®Google Scholar
• Slovin SF, Kehoe M, Durso R, Fernandez C, Olson W, Gao JP, Israel R, Scher HI, Morris S. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 2013; 31:943 - 9; http://dx.doi.org/10.1016/j.vaccine.2012.11.096; PMID: 23246260
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324:1156 - 61; http://dx.doi.org/10.1056/NEJM199104253241702; PMID: 1707140
   PubMed Web of Science ®Google Scholar
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317:909 - 16; http://dx.doi.org/10.1056/NEJM198710083171501; PMID: 2442609
   PubMed Web of Science ®Google Scholar
• Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368:1314 - 25; http://dx.doi.org/10.1056/NEJMoa1212299; PMID: 23550669
   PubMed Web of Science ®Google Scholar
• Sartor O. Androgen deprivation--continuous, intermittent, or none at all?. N Engl J Med 2012; 367:945 - 6; http://dx.doi.org/10.1056/NEJMe1206814; PMID: 22931264
   PubMed Web of Science ®Google Scholar
• Tang S, Dubey P. Opposing effects of androgen ablation on immune function in prostate cancer. Oncoimmunology 2012; 1:1220 - 1; http://dx.doi.org/10.4161/onci.20448; PMID: 23170287
   PubMed Web of Science ®Google Scholar
• Schmidt HH, Ge Y, Hartmann FJ, Conrad H, Klug F, Nittel S, Bernhard H, Domschke C, Schuetz F, Sohn C, et al. HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology 2013; 2:e24962; http://dx.doi.org/10.4161/onci.24962; PMID: 23894725
   PubMed Web of Science ®Google Scholar
• Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen R, Fleming TP. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999; 59:3028 - 31; PMID: 10397237
   PubMed Web of Science ®Google Scholar
• Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 2004; 37:249 - 57; http://dx.doi.org/10.1016/j.clinbiochem.2003.11.005; PMID: 15003725
   PubMed Web of Science ®Google Scholar
• Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Ménétrier-Caux C. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells. Oncoimmunology 2013; 2:e23185; http://dx.doi.org/10.4161/onci.23185; PMID: 23802069
   PubMed Web of Science ®Google Scholar
• Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30:531 - 64; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141623; PMID: 22224781
   PubMed Web of Science ®Google Scholar
• von Boehmer H, Daniel C. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov 2013; 12:51 - 63; http://dx.doi.org/10.1038/nrd3683; PMID: 23274471
   PubMed Web of Science ®Google Scholar
• Blatner NR, Gounari F, Khazaie K. The two faces of regulatory T cells in cancer. Oncoimmunology 2013; 2:e23852; http://dx.doi.org/10.4161/onci.23852; PMID: 23762787
   PubMed Web of Science ®Google Scholar
• Wang D, Rayani S, Marshall JL. Carcinoembryonic antigen as a vaccine target. Expert Rev Vaccines 2008; 7:987 - 93; http://dx.doi.org/10.1586/14760584.7.7.987; PMID: 18767948
   PubMed Web of Science ®Google Scholar
• Sarobe P, Huarte E, Lasarte JJ, Borrás-Cuesta F. Carcinoembryonic antigen as a target to induce anti-tumor immune responses. Curr Cancer Drug Targets 2004; 4:443 - 54; http://dx.doi.org/10.2174/1568009043332916; PMID: 15320719
   PubMed Web of Science ®Google Scholar
• Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J, Van Waes C. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 2002; 62:5049 - 57; PMID: 12208760
   PubMed Web of Science ®Google Scholar
• Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med 2012; 4:127rv2; http://dx.doi.org/10.1126/scitranslmed.3001539; PMID: 22461643
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Hu Y, O’Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2013; 39:219 - 29; http://dx.doi.org/10.1016/j.ctrv.2012.04.008; PMID: 22658319
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011; 9:16 - 32; http://dx.doi.org/10.1038/nrclinonc.2011.177; PMID: 22124364
   PubMed Web of Science ®Google Scholar
• Facciabene A, Aurisicchio L, Elia L, Palombo F, Mennuni C, Ciliberto G, La Monica N. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 2007; 26:47 - 58; http://dx.doi.org/10.1016/j.vaccine.2007.10.060; PMID: 18055074
   PubMed Web of Science ®Google Scholar
• Weltzin R, Guy B, Thomas WD Jr., Giannasca PJ, Monath TP. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun 2000; 68:2775 - 82; http://dx.doi.org/10.1128/IAI.68.5.2775-2782.2000; PMID: 10768972
   PubMed Web of Science ®Google Scholar
• Hyslop T, Waldman SA. Guanylyl cyclase C as a biomarker in colorectal cancer. Biomark Med 2013; 7:159 - 67; http://dx.doi.org/10.2217/bmm.12.90; PMID: 23387497
   PubMed Web of Science ®Google Scholar
• Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, Waldman SA. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci U S A 1996; 93:14827 - 32; http://dx.doi.org/10.1073/pnas.93.25.14827; PMID: 8962140
   PubMed Web of Science ®Google Scholar
• Alexander J, del Guercio MF, Maewal A, Qiao L, Fikes J, Chesnut RW, Paulson J, Bundle DR, DeFrees S, Sette A. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 2000; 164:1625 - 33; PMID: 10640784
   PubMed Web of Science ®Google Scholar
• Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett 2004; 92:259 - 68; http://dx.doi.org/10.1016/j.imlet.2004.01.006; PMID: 15081621
   PubMed Web of Science ®Google Scholar
• Gilbert SC. Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 2013; 31:4241 - 6; http://dx.doi.org/10.1016/j.vaccine.2013.03.020; PMID: 23523410
   PubMed Web of Science ®Google Scholar
• Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 2008; 7:889 - 93; http://dx.doi.org/10.1586/14760584.7.7.889; PMID: 18767940
   PubMed Web of Science ®Google Scholar
• Klein E, Nagy N, Rasul AE. EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency. Oncoimmunology 2013; 2:e23035; http://dx.doi.org/10.4161/onci.23035; PMID: 23526738
   PubMed Web of Science ®Google Scholar
• Smith C, Khanna R. A new approach for cellular immunotherapy of nasopharyngeal carcinoma. Oncoimmunology 2012; 1:1440 - 2; http://dx.doi.org/10.4161/onci.21286; PMID: 23243622
   PubMed Web of Science ®Google Scholar
• Payton S. Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease. Nat Rev Urol 2010; 7:300; http://dx.doi.org/10.1038/nrurol.2010.69; PMID: 20545033
   PubMedGoogle Scholar
• Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, et al, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437 - 46; http://dx.doi.org/10.1016/S0140-6736(10)60172-9; PMID: 20398925
   PubMed Web of Science ®Google Scholar
• Tsao CK, Oh WK. Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks. Nat Rev Clin Oncol 2012; 9:613 - 4; http://dx.doi.org/10.1038/nrclinonc.2012.181; PMID: 23044775
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al, AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187 - 97; http://dx.doi.org/10.1056/NEJMoa1207506; PMID: 22894553
   PubMed Web of Science ®Google Scholar
• Doehn C, Kausch I, Böhmer T, Sommerauer M, Jocham D. Drug evaluation: Therion’s rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine. Curr Opin Mol Ther 2007; 9:183 - 9; PMID: 17458173
   PubMed Web of Science ®Google Scholar
• DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006; 4:1; http://dx.doi.org/10.1186/1479-5876-4-1; PMID: 16390546
   PubMed Web of Science ®Google Scholar
• Geary SM, Salem AK. Prostate cancer vaccines: Update on clinical development. Oncoimmunology 2013; 2:e24523; http://dx.doi.org/10.4161/onci.24523; PMID: 23762812
   PubMed Web of Science ®Google Scholar
• Gerritsen WR. The evolving role of immunotherapy in prostate cancer. Ann Oncol 2012; 23:Suppl 8 viii22 - 7; http://dx.doi.org/10.1093/annonc/mds259; PMID: 22918924
   PubMedGoogle Scholar
• Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 2012; 39:296 - 304; http://dx.doi.org/10.1053/j.seminoncol.2012.02.010; PMID: 22595052
   PubMed Web of Science ®Google Scholar
• Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 2006; 7:599 - 604; http://dx.doi.org/10.1038/sj.embor.7400705; PMID: 16741504
   PubMed Web of Science ®Google Scholar
• Devine PL, McKenzie IF. Mucins: structure, function, and associations with malignancy. Bioessays 1992; 14:619 - 25; http://dx.doi.org/10.1002/bies.950140909; PMID: 1365918
   PubMed Web of Science ®Google Scholar
• Reichenbach DK, Finn OJ. Early in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology 2013; 2:e23429; http://dx.doi.org/10.4161/onci.23429; PMID: 23802084
   PubMed Web of Science ®Google Scholar
• Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, Olmsted R, Houghton AN, Wolchok JD. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 2010; 5:e12670; http://dx.doi.org/10.1371/journal.pone.0012670; PMID: 20844763
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 2010; 120:3234 - 41; http://dx.doi.org/10.1172/JCI42672; PMID: 20679728
   PubMed Web of Science ®Google Scholar
• Atkins GJ, Fleeton MN, Sheahan BJ. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008; 10:e33; http://dx.doi.org/10.1017/S1462399408000859; PMID: 19000329
   PubMedGoogle Scholar
• Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009; 10:118 - 25; http://dx.doi.org/10.2174/138945009787354601; PMID: 19199907
   PubMed Web of Science ®Google Scholar
• Chang SS. Overview of prostate-specific membrane antigen. Rev Urol 2004; 6:Suppl 10 S13 - 8; PMID: 16985927
   PubMedGoogle Scholar
• Galluzzi L. New immunotherapeutic paradigms for castration-resistant prostate cancer. OncoImmunology 2013; 2:e26084; http://dx.doi.org/10.4161/onci.26084
   PubMed Web of Science ®Google Scholar
• Remondo C, Cereda V, Mostböck S, Sabzevari H, Franzusoff A, Schlom J, Tsang KY. Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine 2009; 27:987 - 94; http://dx.doi.org/10.1016/j.vaccine.2008.12.002; PMID: 19110021
   PubMed Web of Science ®Google Scholar
• Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, Quick D, Franzusoff A, Greiner JW, Schlom J, et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 2008; 14:4316 - 25; http://dx.doi.org/10.1158/1078-0432.CCR-08-0393; PMID: 18594015
   PubMed Web of Science ®Google Scholar
• Isaacson P, Judd MA. Carcinoembryonic antigen in medullary carcinoma of thyroid. Lancet 1976; 2:1016 - 7; http://dx.doi.org/10.1016/S0140-6736(76)90847-3; PMID: 62227
   PubMed Web of Science ®Google Scholar
• Ishikawa N, Hamada S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br J Cancer 1976; 34:111 - 5; http://dx.doi.org/10.1038/bjc.1976.133; PMID: 962990
   PubMed Web of Science ®Google Scholar
• Meyer JS, Abdel-Bari W. Granules and thyrocalcitonin-like activity in medullary carcinoma of the thyroid gland. N Engl J Med 1968; 278:523 - 9; http://dx.doi.org/10.1056/NEJM196803072781002; PMID: 5637238
   PubMed Web of Science ®Google Scholar
• Melvin KE, Tashjian AH Jr.. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proc Natl Acad Sci U S A 1968; 59:1216 - 22; http://dx.doi.org/10.1073/pnas.59.4.1216; PMID: 5240025
   PubMed Web of Science ®Google Scholar
• Tashjian AH Jr., Melvin EW. Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts. N Engl J Med 1968; 279:279 - 83; http://dx.doi.org/10.1056/NEJM196808082790602; PMID: 5660301
   PubMed Web of Science ®Google Scholar
• Guirnalda P, Wood L, Goenka R, Crespo J, Paterson Y. Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes. Oncoimmunology 2013; 2:e25752; http://dx.doi.org/10.4161/onci.25752; PMID: 24083082
   PubMed Web of Science ®Google Scholar
• Rothman J, Paterson Y. Live-attenuated Listeria-based immunotherapy. Expert Rev Vaccines 2013; 12:493 - 504; http://dx.doi.org/10.1586/erv.13.34; PMID: 23659298
   PubMed Web of Science ®Google Scholar
• Guirnalda PD, Paterson Y. Vaccination with immunotherapeutic Listeria monocytogenes induces IL-17(+) γδ T cells in a murine model for HPV associated cancer. Oncoimmunology 2012; 1:822 - 8; http://dx.doi.org/10.4161/onci.20491; PMID: 23162749
   PubMed Web of Science ®Google Scholar
• Mustafa W, Maciag PC, Pan ZK, Weaver JR, Xiao Y, Isaacs SN, Paterson Y. Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization. Viral Immunol 2009; 22:195 - 204; http://dx.doi.org/10.1089/vim.2008.0071; PMID: 19435416
   PubMed Web of Science ®Google Scholar
• Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol 2006; 101:524 - 32; http://dx.doi.org/10.1111/j.1572-0241.2006.00443.x; PMID: 16542289
   PubMed Web of Science ®Google Scholar
• Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother 2013; 62:1293 - 301; http://dx.doi.org/10.1007/s00262-013-1400-3; PMID: 23624851
   PubMed Web of Science ®Google Scholar
• Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum Gene Ther 2013; 24:728 - 38; http://dx.doi.org/10.1089/hum.2013.112; PMID: 23902422
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179 - 88; http://dx.doi.org/10.4161/onci.1.2.19026; PMID: 22720239
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; http://dx.doi.org/10.4161/onci.23510; PMID: 23687621
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74 - 88; http://dx.doi.org/10.1016/j.immuni.2013.06.014; PMID: 23890065
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12:385 - 92; http://dx.doi.org/10.1038/nrm3115; PMID: 21527953
   PubMed Web of Science ®Google Scholar
• Hsu A, Ritchie DS, Neeson P. Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?. Oncoimmunology 2012; 1:372 - 4; http://dx.doi.org/10.4161/onci.18963; PMID: 22737619
   PubMed Web of Science ®Google Scholar
• Nasir L. Telomeres and telomerase: Biological and clinical importance in dogs. Vet J 2008; 175:155 - 63; http://dx.doi.org/10.1016/j.tvjl.2007.01.024; PMID: 17398127
   PubMed Web of Science ®Google Scholar
• Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto G, La Monica N, Aurisicchio L. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol Ther 2010; 18:1559 - 67; http://dx.doi.org/10.1038/mt.2010.104; PMID: 20531395
   PubMed Web of Science ®Google Scholar
• Peruzzi D, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 2010; 28:1201 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.11.031; PMID: 19944791
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007; 25:3731 - 41; http://dx.doi.org/10.1016/j.vaccine.2007.01.120; PMID: 17350735
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology 2013; 2:e25396; http://dx.doi.org/10.4161/onci.25396; PMID: 23894726
   PubMed Web of Science ®Google Scholar